On Nov. 16, 2006, Standard&Poor's Ratings Services assigned its 'A+' senior unsecured debt rating to Bristol-Myers Squibb Co.'s €1 billion senior notes, consisting of a 4.375% note due 2016 and a 4.625% note due 2021. Standard&Poor's also assigned its 'A+' senior unsecured rating to the company's $1.25 billion 5.875% notes due Nov. 15, 2036. Proceeds from the notes offering, along with cash on-hand, will be used to tender for the $2.5 billion in outstanding 5.75% notes due 2011. All existing ratings on Bristol-Myers, including the 'A+' long-term corporate credit rating and 'A-1' short-term rating, were affirmed. The rating outlook remains negative. The ratings on New York, N.Y.-based Bristol-Myers reflect the company's diverse product portfolio, promising new-drug
